Bolt Biotherapeutics, Inc. — Director's Dealing 2021

Feb 11, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Bolt Biotherapeutics, Inc. (BOLT)
CIK: 0001641281
Period of Report: 2021-02-09

Reporting Person: Novo Holdings A/S (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-02-09	COMMON STOCK	C	4027088	—	Acquired	4103991	Direct
2021-02-09	COMMON STOCK	P	400000	$20.00	Acquired	4503991	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-09	SERIES A-1 PREFERRED STOCK	$	C	1096323	Disposed		COMMON STOCK (1096323)	Direct
2021-02-09	SERIES B PREFERRED STOCK	$	C	2050758	Disposed		COMMON STOCK (2050758)	Direct
2021-02-09	SERIES C-1 PREFERRED STOCK	$	C	421670	Disposed		COMMON STOCK (421670)	Direct
2021-02-09	SERIES C-2 PREFERRED STOCK	$	C	458337	Disposed		COMMON STOCK (458337)	Direct

Footnotes

F1: Each share of Series A-1 Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock and Series C-2 Preferred Stock (collectively, the "Preferred Stock") converted automatically into one share of Common Stock upon the closing of the Issuer's initial public offering. These shares have no expiration date.

F2: Represents a purchase from the underwriters in the Issuer's initial public offering.